Abstract
Urinary angiotensin converting enzyme 2 (ACE2) is significantly increased in diabetes and diabetic nephropathy. While studies on its clinical significance are still underway, its urinary expression, association with metabolic and renal parameters has been in the recent past considerably studied. The recent studies have demystified urine ACE2 in many ways and suggested the roles it could play in the management of diabetic nephropathy. In all studies the expression of urinary ACE2 was determined by enzyme activity assay and/with the quantification of ACE2 protein and mRNA by methods whose reliability are yet to be evaluated. This review summarizes recent findings on expression of urinary ACE2, examines its relationship with clinical parameters and highlights possible applications in management of diabetic nephropathy.
Highlights
Angiotensin converting enzyme 2 (ACE2) is an intra-renal component of the renin-angiotensin system (RAS) that significantly influences the pathogenesis of diabetic nephropathy [1,2,3]
Significant correlation was found between urinary ACE2 and each of the following parameters; fasting blood glucose, triglycerides, total cholesterol and glycated haemoglobin
No significant correlation was found between urinary ACE2 and renal parameters (ACR and estimated glomerular filtration rate (eGFR))
Summary
Angiotensin converting enzyme 2 (ACE2) is an intra-renal component of the renin-angiotensin system (RAS) that significantly influences the pathogenesis of diabetic nephropathy [1,2,3]. The expression of urinary angiotensin converting enzyme 2 in diabetic subjects with and without nephropathy The protein expression and enzyme activity were significantly increased among diabetic patients [18,19,20,22]. The enzyme activity and ACE2 protein were found expressed as both increased significantly among the diabetic subjects (Table 1).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have